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Summary 
This report reviews experience with 97 patients given 
liver transplants. We regard our survival statistics as 
unsatisfactory, but feel they should encourage further 
", work since II patients have survived at least one year 
with a maximum survival of 5 2/ 3 years. The Achilles' 
heel of liver transplantation is bile duct reconstruction. 
We presently rely upon Roux-en-Y reconstruction, or 
alternatively, duct-tHud anastomosis with aT-tube 
stent. The prime indication for liver replacement is 
non-neoplastic liver disease, but a favourable malig-
nancy for treatment may prove to be small intrahepatic 
duct cell carcinomas. 
DURING the last ten years over 200 patients have had 
liver replacement throughout the world. The Univer-
sity of Colorado Group has contributed 97 cases to 
this total, at a rate of 10 to 20 per year, since 1967, 
when the first long term survival was achieved 
(Starzl and Putnam, 1969). On the basis of this 
experience, we would like to provide a progress re-
port regarding survival statistics, indications for 
operation, our present views about bile duct recon-
struction, and our current programme of immuno-
suppression. 
Survival 
Table 1 depicts our 97 cases. Twenty-two patients 
have lived for-one year after operation, ten for two 
years and six have survived for three years. Two 
have passed the fi'(e years mark and both are alive 
now. Eighteen recipients are still alive, from three 
weeks to 51/, years postoperatively. An I8-year-old 
boy who is alive 52/ 3 years after transplantation 
represents the longest survival after liver transplan-
tation in the world. 
There have been 11 late deaths, from 12 to 41 
months postoperatively, for the reasons listed in 
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TABLE 1. Cases of orthotopic liver transplantation treated 
. in Denver 
Lived 
2 3 5 Alive 
Number year years years years now· 
1963-1966 6 0 0 0 0 0 
1967 6 I 0 0 0 0 
1968 12 5 2 1 0 0 
1969 6 2 1 1 1 1 
1970 10 2 I 1 1 1 
1971 11 2 2 2 0 2 
1972 11 5 3 1 0 2 
1973 13 3 1 0 0 3 
1974 20 2 0 0 0 8 
1975 2 0 0 0 0 I 
97 22 10 6 2 18 
• Longest survivors: 52/. years; 5 years. 
TABLE 2. Present status of 22 one-year 
survivors 
Alive 11/22-12 months to 68 months 
Dead 11/22-12 months to 31 years 
Recurrent cancer-3 
Chronic rejection-2 
Chronic hepatitis-2 
Bile duct obstruction-2 
Other infections-2 
Table 2. Two late deaths were the direct consequence 
of failure of biliary drainage. The latest mortality 
was at three years, five months, and was related to 
an episode of haemophilus septicaemia. Recurrent 
cancer in patients treated for hepatoma caused three 
deaths after one year. This disease has also killed some 
of our patients earlier than this, and we therefore 
consider hepatoma to be a relatively poor indication 
for liver transplantation. However, it is not an abso-
lute contraindication since one of our five year sur-
vivors had a hepatoma in addition to biliary atresia. 
CaIne, and Daloze of Montreal, have also apparently 
cured hepatomas with liver transplantation. 
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Biliary reconstruction 
With only 22 one-year survivors, it is obvious that 
the operation is at present unsafe. The single most 
important factor in the high acute failure rate has 
been a multiplicity of technical misadventures, of 
which complications of biliary duct reconstruc-
tion lead the list. Indeed, this is now the main tech-
nical problem that we face. The different techniques 
we have used to restore bile drainage include 
choledochocholedochostomy with or without a T-
tube, cholecystoduodenostomy after ligation of the 
graft common duct and choledochoduodenostomy. 
Because of continuing dissatisfaction with all of the 
aforementioned techniques of duct reconstruction, 
we have recently embarked on a trial of Roux-en-Y 
cholecystojejunostomy (Starzl et al., 1974). 
None of the commonly used methods of biliary 
duct reconstruction has been trouble-free. With 
cholecystoenterostomy, fistulae are uncommon, but 
obstruction occurs in 25% of the cases. These ob-
structions at the cystic duct (Fig. 1) are sometimes 
due to cytomegalovirus (CMV) infection. Most 
commonly, however, no obvious aetiologic cause 
accounting.for the partial cystic duct obstruction is 
evident. 
Our main objection to choledochocholedochos-
to my is the high incidence, about 50%, of bile fistula 
with subsequent subhepatic sepsis. We are sure that 
bile leak is always going to be a problem in the 
immunosuppressed recipient, so that if one does 
perform a duct-to-duct reconstruction, broad drain-
age, such as by leaving part of the wound wide open, 
must be carried out. Under these conditiQ!)s, we have 
recently employed end-to-end duct reconstruction in 
two adult recipients. One patient is only three weeks 
post-transplantation, but the other is well six months 
after operation. 
With such well-defined technical complications, 
clinical evidence of cholangitis is easily understand-
able and is often accompanied by histopathologic 
FIG. I. Partial cystic duct obstruction following orthotopic liver transplantation. 
Biliary drainage was provided by a Roux-en-Y cholecystojejunostomy. Two months 
after operation the patient suddenly became jaundiced. A transhepatic cholangiogram 
showed a partial obstruction of the cystic duct (small arrow). There was also a leak 
of the ligated common bile duct (large arrows). The patient died of sepsis before a 
secondary reconstruction could be accomplished. 
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findings of cholangitis. In addition, a subtle and as 
yet hypothetical complication may occur in spite of 
an apparently satisfactory biliary duct reconstruc-
tion. We have reported that systemic infection and 
even asymptomatic bacteraemia are common prob-
lems in liver patients (Starzl and Putnam, 1969). In 
the liver recipients with bacteraemia, the failure to 
find any other focus of infection necessitates indict-
ment of the homograft, as the site of entry, by the 
process of exclusion. The two possible routes of entry 
could be the portal vein or the duct system, but the 
latter seems the more likely to us. 
The exposed relation of the duct system of the 
orthotopic liver to gastrointestinal flora is probably 
the first step in bacterial 'leak' through the homograft 
which may well be bacteriologically porous without 
0.,,,.,,.·· !if!JjJ 
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the presence of histopathologically significant cholan-
gitis. If bacteria enter the circulation through the duct 
system of hepatic homografts, the logical solution 
would be to carry out liver transplantation as far re-
moved from the mainstream of the gastrointestinal 
tract as is possible (Fig. 2). The alternative would be 
to retain the sphincter of Oddi by using a choledo-
chocholedochostomy with the important secondary 
defence provided by massive drainage. 
Obviously, we are recommending individualiza-
tion of biliary duct reconstruction depending upon 
the circumstances of the case. But whatever the 
original technique, the development of either jaun-
dice or systemic sepsis should cause intensification 
of diagnostic efforts to differentiate between duct 
obstruction and rejection. We always perform 
FIG. 2. Relative bacterial contamination with three kinds of biliary reconstruction. 
(A) Cholecystoduodenostomy. This procedure is the simplest, but probably carries 
the greatest risk of infection of the graft. (B) Roux-en-Y cholec:ystojcjunostomy. The 
liver is protected from bacterial contamination by creating an isoperistaltic limb of 
jejunum, 18 inches in length, isolating the biliary tree from the gastrointestinal tract. 
(C) Roux-en-Y choledochojejunostomy. A duct-to-bowel anastomosis is simple if the 
duct has become dilated. as would be the case if a conversion from B to C became 
necessary because of a cystic duct obstruction. (By permission of rrQnsplQntQlion 
Procudings, 6, 129. 1974.) 
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intravenous cholangiography in the early post-
operative period. In almost all of our patients who 
develop jaundice, transhepatic cholangiography (Fig. 
I) and, frequently, percutaneous needle biopsy are 
performed. Cholangiography has been greatly 
expedited by the use of a thin-walled, small calibre 
needle which has great flexibility, permitting the 
diagnostic studies to be done with increased safety. 
Indications 
Indications for liver transplantation are becoming 
increasingly clear. Although we do not consider 
hepatomas to be a good indication, we have 
done three cases of small, unresectable duct cell 
carcinomas which were located at the bifurcation of 
the intrahepatic ducts (Fig. 3). Two of these patients 
are still alive, one at six months and the other one 
year after transplantation. Neither has evidence of 
recurrence. 
The best candidates for liver replacement are those 
with non-neoplastic liver disease. Biliary atresia, 
chronic aggressive hepatitis and Wilson's disease are 
disorders with which we have had mJ,!ltiple successes. 
Our worst results have been with alcoholics. Ten of 
11 patients with end-stage Laennec's cirrhosis have 
died from three to 121 days post· transplantation. 
FIG. 3. Cholangioc:arcinoma. diagnosed by transhepatic cholangiography. and treated 
by orthotopic hepatic transplantation, The patient is well one year later. G B = gall 
bladder; CD = common duct. 
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The only surviving recipient is in good condition ten 
months postoperative. If liver transplantation is to 
succeed in patients with alcoholic cirrhosis, potential 
recipients must be selected earlier, treated aggressively 
to prevent or correct infectious, pulmonary or other 
complications, and transplanted before their con-
dition has markedly deteriorated. 
Immunosuppression 
Finally, a few words about immunosuppression, 
particularly antilymphocyte globulin. Our regimen 
of immunosuppression for liver transplantation has 
not changed appreciably in seven years. We use 
azathioprine and prednisone from the start. If we 
suspect hepatotoxicity from the azathioprine, we 
change to cyclophosphamide. Superimposed on 
these two drugs is a one-month course of anti-
lymphocyte globulin. We are now using horse anti-
lymphoblast globulin raised according to the 
schedules developed by Groth et al. (1972). In the 
average adult we give 4 ml per day for two weeks, 
then alternate days for another two weeks. We have 
not tried any kind of controlled study in our liver 
recipients-there are far too many variables and too 
few cases-but we are sure that our thinking about 
antilymphocyte globulin in these patients will be in-
fluenced by the information shared at this conference 
and by what we see in controlled trials in renal 
recipients. 
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Discussion 
HOBBS: As all your patients had ALG we cannot draw 
any conclusions about its role in liver transplantation, but 
I would like to know if any of your patients developed a 
cholestatic jaundice unrelated to technical surgical prob-
lems. My reason for asking is that two other cases who 
had ALG for bone marrow transplantation, as well as~· 
the one I reported, developed a cholestatic jaundice. I 
think that this is almost certainly a form of chronic graft-
versus-host reaction but it could be an unknown side 
effect of ALG. 
PUTNAM: We have had some cases of cholestatic 
jaundice but then this is a very prominent finding in 
rejection of liver grafts. It is difficult to separate drug 
related cholestasis from rejection. On biopsy using 
immunofluorescent techniques we have not found any 
evidence that ALG could be a causative factor. 
CALNE (Cambridge. United Kingdom): It is quite pos-
sible to perform liver grafts without ALG. We have done 
40 cases to date and our rejection rate would appear to be 
slightly less than yours. We have had many problems 
with bile drainage. 
The concept of maximum immunosuppression may 
well be wrong in all kinds of organ grafting, but especially 
in liver grafting. We have been able to have patients with 
liver transplants off steroids entirely which is something 
we have never been able to do in kidney graft patients. 
I feel the idea of the liver being less likely to reject is 
true for man as well as other species. 
I was also particularly pleased to hear that you had 
gone back to using azathioprine as a primary immuno-
suppressant drug. Our early experimental work with 
cyclophosphamide suggested that it was a much less 
satisfactory immunosuppressant in kidney grafts in dogs, 
although it destroyed lymphocytes more efficiently than 
azathioprine. Naturally it is useful to have cyclophos-
phamide as an alternative if the azathioprine causes 
hepatotoxicity but all in all I feel azathioprine is a better 
immunosuppressant. 
PUTNAM: I agree entirely with your comments regarding 
the liver graft and the need for immunosuppression. One 
thing we have come to realize is the tremendous flexi-
bility required in the immunosuppressive regime if one is 
to achieve success in a liver graft. Some patients require 
absolute minimal suppression. Although we usually start 
with fairly large doses of prednisone, we attempt to reduce 
them rapidly. In some cases, with potential septic problems, 
we commence with a very small dose, and maintain this 
until obvious signs of rejection occur. In some of these 
latter cases this never happens. Thus alI in all the liver 
may well be less susceptible to rejection. 
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